UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/935,100	08/22/2001	David B. Weiner	UPN-4099	2243

7590 04/09/2007

COZEN O'CONNER
1900 MARKET STREET
PHILADELPHIA, PA 19103

EXAMINER	
PARKIN, JEFFREY S	
ART UNIT	PAPER NUMBER
1648	

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	04/09/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

DEA/FCE-1994

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/935,100	08/22/01	Weiner, D. B., et al.	UPVG0003-103

EXAMINER	
Jeffrey S. Parkin, Ph.D.	
ART UNIT	PAPER NUMBER
1648	04/01/2007

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application
Commissioner of Patents

The communication filed on 28 December, 2006, is non-responsive to the prior Office action. The response contained numerous illegible (particularly the claims) portions. Since the response appears to be *bona fide*, but through an apparent oversight or inadvertence failed to provide a complete response, applicant is given a **TIME PERIOD** of **ONE (1) MONTH** or **THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. **EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 C.F.R. § 1.136(a).**

Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (571) 272-0908. The examiner can normally be reached Monday through Thursday from 10:30 AM to 9:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Bruce R. Campell, Ph.D., can be reached at (571) 272-0974. Direct general status inquiries to the Technology Center 1600 receptionist at (571) 272-1600. Informal communications may be submitted to the Examiner's RightFAX account at (571) 273-0908.

Applicants are reminded that the United States Patent and Trademark Office (Office) requires most patent related correspondence to be: a) faxed to the Central FAX number (571-273-8300) (updated as of July 15, 2005), b) hand carried or delivered to the Customer Service Window (now located at the Randolph Building, 401 Dulany Street, Alexandria, VA 22314), c) mailed to the mailing address set forth in 37 C.F.R. § 1.1 (e.g., P.O. Box 1450, Alexandria, VA 22313-1450), or d) transmitted to the Office using the Office's Electronic Filing

System. This notice replaces all prior Office notices specifying a specific fax number or hand carry address for certain patent related correspondence. For further information refer to the Updated Notice of Centralized Delivery and Facsimile Transmission Policy for Patent Related Correspondence, and Exceptions Thereto, 1292 Off. Gaz. Pat. Office 186 (March 29, 2005).

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Respectfully,

Jeffrey S. Parkin, Ph.D.
Primary Examiner
Art Unit 1648

01 April, 2007

Doc :et No.: UPVG0003-103
API L. NO. 09/935,100

PATENT
Filed: 08/22/2001

AM :NDMENTS TO THE CLAIMS:

Please amend claims 37 and add new claims 47-51.

This listing of claims will replace all prior versions, and listings, of claims in the appli :ation:

1-31. **(Canceled)**

32. (Previously presented) A pharmaceutical composition comprising
a) anti-Vpr monoclonal antibodies; and
b) a pharmaceutically acceptable carrier.

33. (Previously presented) A method of treating an individual exposed to HIV by admi) istering an effective amount of anti-Vpr antibodies.

34. (Previously presented) A method of treating an individual who has been infected with HIV comp ising the step of administering to said individual a therapeutically effective amount of anti-Vpr a tibodies.

35. (Canceled)

36. (Previously presented) The pharmaceutical composition of claim 32 wherein the anti-Vpr antibc lies bind to a fragment of Vpr comprising amino acids 2-12.

37. (Currently amended) A pharmaceutical composition comprising:
a) anti-Vpr antibodies that inactivate Vpr activity to reduce the rate of HIV viral produ tion; ~~inhibit Vpr enhancement of HIV replication;~~ and

b) a pharmaceutically acceptable carrier;

wherein the anti-Vpr antibodies are present in an amount effective to reduce the rate of viral production ~~inhibit HIV replication~~ in an HIV infected individual.

38. (Previously presented) The pharmaceutical composition of claim 37 wherein the anti-Vpr antibodies are monoclonal antibodies.

39. (Canceled)

40. (Previously presented) The pharmaceutical composition of claim 37 wherein the composition is a sterile composition and the anti-Vpr antibodies bind to a fragment of Vpr comprising amino acids 2-12.

41. (Previously presented) The method of claim 33 wherein the anti-Vpr antibodies are monoclonal antibodies.

42. (Canceled)

43. (Previously presented) The method of claim 33 wherein the anti-Vpr antibodies bind to a fragment of Vpr comprising amino acids 2-12.

44. (Previously presented) The method of claim 34 wherein the anti-Vpr antibodies are monoclonal antibodies.

45. (Canceled)

46. (Previously presented) The method of claim 34 wherein the anti-Vpr antibodies bind to a fragment of Vpr comprising amino acids 2-12.

47. (New) The pharmaceutical composition of claim 32 wherein the anti-Vpr antibodies are present in an amount effective to reduce the rate of viral production in an HIV infected individual.

48. (New) The method of claim 34 wherein the anti-Vpr antibodies inactivate Vpr activity to reduce the rate of HIV viral production.

49. (New) The method of claim 48 wherein the anti-Vpr antibodies are monoclonal antibodies.

50. (New) The method of claim 34 wherein the anti-Vpr antibodies inactivate Vpr activity to reduce the rate of HIV viral production.

51. (New) The method of claim 50 wherein the anti-Vpr antibodies are monoclonal antibodies.